×
About 280 results

ALLMedicine™ Acute Megakaryoblastic Leukemia Center

Research & Reviews  105 results

Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syn...
https://doi.org/10.1080/10428194.2022.2140285
Leukemia & Lymphoma; Chen Wongworawat Y, Eskandari G et. al.

Nov 9th, 2022 - Frequent detection of CBFA2T3::GLIS2 fusion and RAM-phenotype in pediatric non-Down syndrome acute megakaryoblastic leukemia: a possible novel relationship with aberrant cytoplasmic CD3 expression.|2022|Chen Wongworawat Y,Eskandari G,Gaikwad A,Mar...

JAK: Not Just Another Kinase.
https://doi.org/10.1158/1535-7163.MCT-22-0323
Molecular Cancer Therapeutics; Agashe RP, Lippman SM et. al.

Oct 18th, 2022 - The Janus kinase/signal transducer and activator of transcription (JAK/STAT) axis is implicated in cancer, inflammation, and immunity.Numerous cytokines/growth factors affect JAK/STAT signaling. JAKs noncovalently associate with cytokine receptors...

ALL-124 Outcome of Acute Leukemia in Down Syndrome: A Retrospective Experience of Ain S...
https://doi.org/10.1016/S2152-2650(22)01184-3
Clinical Lymphoma, Myeloma & Leukemia; Makkeyah S, Elsayed SM et. al.

Sep 28th, 2022 - Children with Down syndrome are at an elevated risk of acute leukemia, namely myeloid leukemia (ML-DS) and acute lymphoblastic leukemia (DS-ALL), though the higher risk of developing leukemia remains largely unclear. This malignancy is frequently ...

CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663156
The Journal of Clinical Investigation; Le Q, Hadland B et. al.

Sep 23rd, 2022 - The CBFA2T3-GLIS2 (C/G) fusion is a product of a cryptic translocation primarily seen in infants and early childhood and is associated with dismal outcome. Here, we demonstrate that the expression of the C/G oncogenic fusion protein promotes the t...

Dissecting stepwise mutational impairment of megakaryopoiesis in a model of Down syndro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282920
The Journal of Clinical Investigation; Evans EJ, DeGregori J

Jul 16th, 2022 - Individuals with Down syndrome (DS) have more than 100-fold increased risk of acute megakaryoblastic leukemia (AMKL), but its pathogenesis is poorly understood. In this issue of the JCI, Arkoun et al. engineered stepwise DS-AMKL-associated mutatio...

see more →

Clinicaltrials.gov  5 results

Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT02530619

May 26th, 2021 - PRIMARY OBJECTIVES: I. Determine the safety profile of alisertib in patients with acute megakaryoblastic leukemia (AMKL) and in patients with myelofibrosis (MF). SECONDARY OBJECTIVES: I. Determine preliminary efficacy of alisertib in both populati...

Study of Bone Marrow Samples From Patients With Acute Leukemia
https://clinicaltrials.gov/ct2/show/NCT00897559

May 17th, 2017 - OBJECTIVES: To perform high throughput sequencing of a set of megakaryocyte specific transcription factors, tyrosine kinases, and Src kinases in DNA isolated from bone marrow specimens of adults with acute megakaryoblastic leukemia (AMKL). To assa...

Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01642069

May 18th, 2016 - Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Cryopreserved mRNA Study Population Description: Samples from AAML0531 Sampling...

Biomarkers in Samples From Patients With Down Syndrome and Acute Megakaryoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT01139307

Feb 23rd, 2016 - OBJECTIVES: Determine whether megakaryocyte differentiation agents comprising a Rho kinase inhibitor and a JAK3 inhibitor can lead to proliferation arrest, polyploidization, and terminal differentiation of blasts in specimens from patients with Do...

A Pilot Study of ODSH in Acute Myeloid Leukemia
https://clinicaltrials.gov/ct2/show/NCT02056782

Feb 16th, 2015 - This is an open-label, multi-center, 10 patient pilot study with an anticipated 1 year enrollment period Primary Objectives: To evaluate the safety and tolerability of ODSH in patients with Acute Myeloid Leukemia (AML) receiving cytarabine and ida...

see more →

News  2 results

New recommendations for pediatric AMKL
https://www.mdedge.com/hematology-oncology/article/186901/leukemia-myelodysplasia-transplantation/new-recommendations-pediatric-amkl
HT Staff

Jan 24th, 2017 - Micrograph showing AMKL Image courtesy of St. Jude Children’s Research Hospital and Tina Motroni Research has revealed genetic alterations that may prove useful for predicting treatment outcomes in pediatric patients with acute megakaryoblastic le.

Team identifies new mechanism of megakaryocyte differentiation
https://www.mdedge.com/hematology-oncology/article/188547/leukemia-myelodysplasia-transplantation/team-identifies-new-mechanism
HT Staff

Jan 13th, 2016 - Megakaryocytes in the bone marrow Investigators have discovered a new mechanism of megakaryocyte differentiation, according to a paper published in eLife. They found that overexpression of the methyltransferase enzyme PRMT1 in acute megakaryocytic.

see more →